Buntanetap shows early potential for Parkinson’s-related dementia

US biotech Annovis Bio (NYSE: ANVS) has reported encouraging findings for its experimental therapy buntanetap in a subgroup of patients with early-stage Parkinson’s disease and mild dementia.

The data, presented at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases, suggest buntanetap may help address both motor and cognitive symptoms in this patient group — a segment where treatment options remain limited.

Although the study missed its primary endpoint in the full intention-to-treat population, the drug showed potential benefits in a subgroup of patients with a Mini Mental State Examination score between 20 and 26. These participants, treated with 20mg of buntanetap over six months, experienced stable cognition and improvements in several clinical measures of motor and daily function.